ErbB 4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy

blockage can be used as a target for anti-cancer therapy Alex Starr* , Joel Greif* , Akiva Vexler, Maia Ashkenazy-Voghera, Valery Gladesh, Chanan Rubin, Gabriele Kerber, Sylvia Marmor, Shahar Lev-Ari, Moshe Inbar, Yosef Yarden and Rami Ben-Yosef Lung and Allergy Institute, Tel-Aviv Sourasky Medical Center and Tel-Aviv University School of Medicine, Tel-Aviv, Israel Division of Oncology, Tel-Aviv Sourasky Medical Center and Tel-Aviv University School of Medicine, Tel-Aviv, Israel Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel Division of Pathology, Tel-Aviv Sourasky Medical Center and Tel-Aviv University School of Medicine, Tel-Aviv, Israel

[1]  Y. Yarden,et al.  Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Ardizzoni,et al.  Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer. , 2004, Current medicinal chemistry. Anti-cancer agents.

[3]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[4]  B. Angus,et al.  Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4 , 2003, Journal of clinical pathology.

[5]  D. Riese,et al.  A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. , 2003, Cancer letters.

[6]  G. Carpenter,et al.  ErbB-4: mechanism of action and biology. , 2003, Experimental cell research.

[7]  T. Curran,et al.  ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  M. Inbar,et al.  ErbB-4 expression in limb soft-tissue sarcoma: correlation with the results of neoadjuvant chemotherapy. , 2002, European journal of cancer.

[9]  J. Nesland,et al.  EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival , 2002, The Journal of pathology.

[10]  R. Allibone,et al.  Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma , 2001, Genes, chromosomes & cancer.

[11]  J. Greif,et al.  Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small-cell lung cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Smyth,et al.  Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. , 2001, Cancer research.

[13]  O. Stoeltzing,et al.  Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer , 2000, British Journal of Cancer.

[14]  R. Narayanan,et al.  HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test. , 2000, Anticancer research.

[15]  M. Klagsbrun,et al.  A Natural ErbB4 Isoform That Does Not Activate Phosphoinositide 3-Kinase Mediates Proliferation but Not Survival or Chemotaxis* , 2000, The Journal of Biological Chemistry.

[16]  D. Barnes,et al.  Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. , 2000, Cancer research.

[17]  M. Sliwkowski,et al.  Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells , 1999, Oncogene.

[18]  W. Gullick,et al.  Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 Growth Factor Receptors and Their Ligands, Neuregulin-1 α, Neuregulin-1 β, and Betacellulin, in Normal Endometrium and Endometrial Cancer , 1999 .

[19]  H. Friess,et al.  ErbB‐4 mRNA expression is decreased in non‐metastatic pancreatic cancer , 1999, International journal of cancer.

[20]  M. Kraus,et al.  Immune responses to all ErbB family receptors detectable in serum of cancer patients , 1999, Oncogene.

[21]  I. Ellis,et al.  c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer , 1998, Oncogene.

[22]  J. Lunec,et al.  Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. , 1998, Cancer research.

[23]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[24]  R. Poulsom,et al.  Expression of the c‐erbB‐4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types , 1998, The Journal of pathology.

[25]  D. Stern,et al.  Activation of ErbB4 by the Bifunctional Epidermal Growth Factor Family Hormone Epiregulin Is Regulated by ErbB2* , 1998, The Journal of Biological Chemistry.

[26]  R. Sutherland,et al.  Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40. , 1998, Cancer research.

[27]  K. Kelly,et al.  New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  R H Perry,et al.  Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. , 1997, Cancer research.

[29]  M. Klagsbrun,et al.  Activation of HER4 by heparin‐binding EGF‐like growth factor stimulates chemotaxis but not proliferation , 1997, The EMBO journal.

[30]  O. Bogler,et al.  A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.

[31]  Y. Yarden,et al.  Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. , 1996, Oncogene.

[32]  Y. Yarden,et al.  An Immunological Approach Reveals Biological Differences between the Two NDF/Heregulin Receptors, ErbB-3 and ErbB-4 (*) , 1996, The Journal of Biological Chemistry.

[33]  L. Akslen,et al.  Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. , 1996, Cancer research.

[34]  Y. Yarden,et al.  Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. , 1996, The American journal of pathology.

[35]  T. van Raaij,et al.  Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. , 1996, Oncogene.

[36]  W. Richards,et al.  Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  Y. Yarden,et al.  Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior. , 1994, The American journal of pathology.

[38]  E. Peles,et al.  ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. , 1994, The Journal of biological chemistry.

[39]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Plowman,et al.  Heregulin induces tyrosine phosphorylation of HER4/p180erbB4 , 1993, Nature.

[41]  G. Plowman,et al.  Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Weiner,et al.  p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.

[43]  F. Hamdy,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[44]  H. Juhl,et al.  Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. , 2001, International journal of surgical investigation.

[45]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[46]  Y. Yarden,et al.  Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.

[47]  D. Stern,et al.  Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. , 1999, The American journal of physiology.

[48]  M. O’Connor-McCourt,et al.  Expression of P185erbB-2, P160erbB-3, P180erbB-4, and heregulin alpha in human normal bronchial epithelial and lung cancer cell lines. , 1999, Anticancer research.

[49]  M. Melhem,et al.  Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. , 1997, The cancer journal from Scientific American.

[50]  M. Kelley,et al.  Genetic mechanisms of solid tumor oncogenesis. , 1994, Advances in internal medicine.